Tofacitinib approved by NICE for severe rheumatoid arthritis

The JAK inhibitor tofacitinib (Xeljanz) has been endorsed by NICE for use in patients with severe rheumatoid arthritis (RA) who have not responded to DMARDs.

by Sandhiya Sodha
Rheumatoid arthritis can cause a range of debilitating symptoms, including pain and swelling in the joints, tiredness and depression. | SCIENCE PHOTO LIBRARY
Rheumatoid arthritis can cause a range of debilitating symptoms, including pain and swelling in the joints, tiredness and depression. | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package